Armata Pharmaceuticals, Inc. ARMP
Armata Pharmaceuticals, Inc. (NYSE: ARMP) is an infectious disease drug developer. Its lead program, AP-SA02, is in Phase 2 for Complicated Staphylococcus aureus bacteremia (adjunct to best available antibiotic therapy). Its next catalyst on record is AP-SA02: Initiation of pivotal Phase 3 superiority study in complicated S. aureus bacteremia (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AP-SA02 — Initiation of pivotal Phase 3 superiority study in complicated S. aureus bacteremia (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AP-SA02 (IV phage) | Complicated S. aureus bacteremia | biologic-other | Phase 2 |
| AP-PA02 (inhaled phage) | Chronic P. aeruginosa lung infection in non-CF bronchiectasis / cystic fibrosis | biologic-other | Phase 2 |
| AP-SA02 (PJI / wound infection) | S. aureus prosthetic joint and wound infections | biologic-other | Pre-clinical |
| AP-PA03 (IV phage) | P. aeruginosa ventilator-associated pneumonia | biologic-other | Pre-clinical |
Recent results and decisions
- Sep 14, 2026n/a FDA granted Breakthrough Therapy designation to AP-SA02 based on Phase 2 diSArm data (100% vs 75% maintained clinical response at end of study vs placebo).
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia.
Filing - May 7, 2026n/a FDA granted Fast Track Designation to AP-SA02 for complicated S. aureus bacteremia, enabling rolling BLA review.
The U.S. Food and Drug Administration has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aur
Filing - Oct 22, 2025positive IDWeek 2025 presentation of Phase 2a diSArm: AP-SA02 plus best available antibiotics showed earlier and higher clinical response than placebo (p=0.047 at Day 12 by blinded PI), with a safe and well-tolerated profile.
In combination with BAT, AP-SA02 had an earlier and higher cure rate compared to placebo in patients with complicated SAB at day 12, post BAT, and at EOS.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.